High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.
Ellen Kelsay, BA
Advertisement
Articles by Ellen Kelsay, BA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
2
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
3
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
4
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
5